Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CALCRL | Q16602 | 12/20 | 0.41 |
| ▸ | CALCA | P06881 | 1/20 | 0.37 |
| ▸ | MCHR1 | Q99705 | 3/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5375083 | 0.88 | CALCRL (0.52) | CALCRLCALCA | |
| SCHEMBL5367564 | 0.87 | CALCRL (0.43) | CALCRLCALCAMCHR1SMN1; SMN2 | |
| SCHEMBL5369205 | 0.85 | CALCRL (0.45) | CALCRLCALCASMN1; SMN2 | |
| SCHEMBL5387757 | 0.78 | CALCRL (0.56) | CALCRLCALCA | |
| SCHEMBL5376454 | 0.75 | CALCRL (0.44) | CALCRLCALCAKMT2ASMN1; SMN2 | |
| SCHEMBL5371697 | 0.75 | CALCRL (0.59) | CALCRLCALCA | |
| SCHEMBL5372030 | 0.75 | CALCRL (0.55) | CALCRLCALCACYP3A4 | |
| SCHEMBL5369994 | 0.74 | HSD11B1 (0.51) | CYP2D6 | |
| SCHEMBL5378609 | 0.73 | CALCRL (0.54) | CALCRLCALCA | |
| SCHEMBL5371970 | 0.73 | CALCRL (0.49) | CALCRLSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070208036-A1 | Arylalkanes, arylalkenes and aryl-azaalkanes, pharmaceutical compositions containing these compounds and processes for preparing them | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2007-09-06 | — | — | US | disclosed |
| US-7230001-B1 | Arylalkane, arylalkene and aryl azaalkane, medicaments containing said compounds and method for the production thereof | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2007-06-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070208036-A1 | Arylalkanes, arylalkenes and aryl-azaalkanes, pharmaceutical compositions containing these compounds and processes for preparing them | ARRB1, NPY1R, ADRB3 | CALCRL 4/4885CALCA 9/4885MCHR1 466/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.